Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages.

Arlauckas SP, Garren SB, Garris CS, Kohler RH, Oh J, Pittet MJ, Weissleder R.

Theranostics. 2018 Nov 12;8(21):5842-5854. doi: 10.7150/thno.26888. eCollection 2018.

2.

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.

Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ.

Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11.

PMID:
30552023
3.

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.

Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, Kohler RH, Pittet MJ, Weissleder R.

Nat Biomed Eng. 2018;2:578-588. Epub 2018 May 21.

4.

Recording the wild lives of immune cells.

Pittet MJ, Garris CS, Arlauckas SP, Weissleder R.

Sci Immunol. 2018 Sep 7;3(27). pii: eaaq0491. doi: 10.1126/sciimmunol.aaq0491. Review.

PMID:
30194240
5.

IRF3 and type I interferons fuel a fatal response to myocardial infarction.

King KR, Aguirre AD, Ye YX, Sun Y, Roh JD, Ng RP Jr, Kohler RH, Arlauckas SP, Iwamoto Y, Savol A, Sadreyev RI, Kelly M, Fitzgibbons TP, Fitzgerald KA, Mitchison T, Libby P, Nahrendorf M, Weissleder R.

Nat Med. 2017 Dec;23(12):1481-1487. doi: 10.1038/nm.4428. Epub 2017 Nov 6.

PMID:
29106401
6.

In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.

Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, Weissleder R, Pittet MJ.

Sci Transl Med. 2017 May 10;9(389). pii: eaal3604. doi: 10.1126/scitranslmed.aal3604.

7.

Near infrared fluorescent imaging of choline kinase alpha expression and inhibition in breast tumors.

Arlauckas SP, Kumar M, Popov AV, Poptani H, Delikatny EJ.

Oncotarget. 2017 Mar 7;8(10):16518-16530. doi: 10.18632/oncotarget.14965.

8.

Choline kinase alpha-Putting the ChoK-hold on tumor metabolism.

Arlauckas SP, Popov AV, Delikatny EJ.

Prog Lipid Res. 2016 Jul;63:28-40. doi: 10.1016/j.plipres.2016.03.005. Epub 2016 Apr 9. Review.

9.

Quantification of tumor fluorescence during intraoperative optical cancer imaging.

Judy RP, Keating JJ, DeJesus EM, Jiang JX, Okusanya OT, Nie S, Holt DE, Arlauckas SP, Low PS, Delikatny EJ, Singhal S.

Sci Rep. 2015 Nov 13;5:16208. doi: 10.1038/srep16208.

10.

Magnetic resonance spectroscopy for detection of choline kinase inhibition in the treatment of brain tumors.

Kumar M, Arlauckas SP, Saksena S, Verma G, Ittyerah R, Pickup S, Popov AV, Delikatny EJ, Poptani H.

Mol Cancer Ther. 2015 Apr;14(4):899-908. doi: 10.1158/1535-7163.MCT-14-0775. Epub 2015 Feb 5.

11.

Direct inhibition of choline kinase by a near-infrared fluorescent carbocyanine.

Arlauckas SP, Popov AV, Delikatny EJ.

Mol Cancer Ther. 2014 Sep;13(9):2149-58. doi: 10.1158/1535-7163.MCT-14-0085. Epub 2014 Jul 15.

Supplemental Content

Loading ...
Support Center